The breast cancer death rate is declining significantly and more women are surviving longer, according to a special report in Canadian Cancer Statistics 2007, released by the Canadian Cancer Society.
Recently, there have been several advances in treatment and therapy for breast cancer. However, the rate of recurrence is still unpredictable. Researchers at West Virginia University have discovered a gene pattern for identifying a patient?s odds of breast cancer recurrence.
Data demonstrating genetic differences in individuals? susceptibility to certain cancers as well as differences in how people respond to specific cancer treatments will take center stage when more than 17,000 scientists from around the world gather at the Los Angeles Convention Center April 14-18 for the 2007 Annual Meeting of the American Association for Cancer Research (AACR). Key data presented at the meeting will also include findings related to the safety and effectiveness of several new, high-profile cancer therapies and vaccines.
Researchers at the Kimmel Cancer Center at Jefferson have identified a protein that they say is key to helping a quarter of all breast cancers spread. The finding, reported online the week of April 9, 2007 in the journal Proceedings of the National Academy of Sciences, could be a potential target for new drugs aimed at stopping or slowing the growth and progression of breast cancer.
A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time (DT) is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer.
Patients who undergo a minimally invasive lung cancer surgery called thoracoscopic lobectomy may derive more benefit from the chemotherapy that follows, according to Duke University Medical Center researchers.
A mouse model for synovial sarcoma has enabled scientists to make tremendous progress toward understanding the origin and pathogenesis of this highly aggressive soft-tissue malignancy.
Virologists in the Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM) at Virginia Tech are looking at how a genetically modified variant of Avian Newcastle disease virus (NDV) can treat human prostate cancer.
A leading expert on modern day management of cancer is calling for the implementation of proper procedures that would allow NHS patients to top up cancer care in the private sector.
A new study provides evidence that racial differences in the clinical presentation of breast cancer may be due more to biological factors rather than differences in access to health care alone.